

SUPPLEMENTARY DATA

Acknowledgements and Disclosures

RAS acts as guarantor for the manuscript.

We are extremely grateful to The Genetic Investigation of ANthropometric Traits (*GIANT*) consortium for providing data on SNP associations with BMI from their published meta-analysis.

Inês Barroso is grateful to the Wellcome Trust (Grant number **098051**), the NIHR Cambridge Biomedical Research Centre and the MRC Centre for Obesity and Related Metabolic Diseases for funding support.

ARIC: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.

PPP-Botnia: We thank the participants in the study as well as the Botnia Study Group. We are also grateful for the technical assistance of the staff of the CRC in Malmö. This work was funded in part by grants from the Swedish Diabetes Association, Swedish Heart Lung-Foundation, Novo Nordisk, the Knut and Alice Wallenberg Foundation, the Pålsson Foundation, the Sigrid Juselius Foundation, the Folkhälsan Research Foundation, the Nordic Center of Excellence in Disease Genetics, an EU grant (EXGENESIS), the Signe and Ane Gyllenberg Foundation, the Swedish Cultural Foundation in Finland, the Finnish Diabetes Research Foundation, the Foundation for Life and Health in Finland, the Finnish Medical Society, the Paavo Nurmi Foundation, Helsinki University Central Hospital Research Foundation, the Perklén Foundation, the Ollqvist Foundation and the Närpes Health Care Foundation.

CHS: The CHS research reported in this article was supported by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant numbers U01 HL080295 and R01 HL087652 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at <http://www.chs-nhlbi.org/pi.htm>. DNA handling and genotyping was supported in part by National Center for Research Resources grant M01-RR00425 to the Cedars-Sinai General Clinical Research Center Genotyping core and National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

CoLaus: The CoLaus study was supported by research grants from GlaxoSmithKline and from the Faculty of Biology and Medicine of Lausanne, Switzerland, and is currently supported by Swiss National Science Foundation (grant no: 33CSCO-122661). S Bergmann is grateful for financial support from the Giorgi-Cavaglieri Foundation, the Swiss National Science Foundation (Grant #3100AO-116323/1), the Swiss Institute of Bioinformatics and the European Framework Project 6 (through the AnEuploidy and EuroDia projects). **Disclosures:** GW and PV received an unrestricted grant from GlaxoSmithKline for collecting the CoLaus data.

SUPPLEMENTARY DATA

Ely: The Ely Study was funded by the MRC and Diabetes UK. Additional support was provided by the Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and the Wellcome Trust. We are grateful to all volunteers who gave their time to take part in the study.

Fenland: The Fenland Study is funded by the Wellcome Trust and the Medical Research Council. We thank the study participants, general practitioners, and the study team. We also thank the NIHR Cambridge Biomedical Research Centre for biochemical analyses.

Framingham: This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This work was partially supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01 - HC - 25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02 - HL - 6 - 4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA - II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. Also supported by National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK078616 to Drs. Meigs, Dupuis and Florez, NIDDK K24 DK080140 to Dr. Meigs, and a Massachusetts General Hospital Physician Scientist Development Award and a Doris Duke Charitable Foundation Clinical Scientist Development Award to Dr. Florez. **Disclosures:** JCF has received consulting honoraria from Daiichi-Sankyo and AstraZeneca.

FUSION: Support for FUSION was provided by NIH grants R01-DK062370 (to M.B.) and intramural project number 1Z01-HG000024 (to F.S.C.). Genome-wide genotyping was conducted by the Johns Hopkins University Genetic Resources Core Facility SNP Center at the Center for Inherited Disease Research (CIDR), with support from CIDR NIH contract no. N01-HG-65403.

GLACIER: The authors thank the participants in the GLACIER Study, the staff of the Umeå Medical Biobank for preparing the materials, and the Västerbotten Intervention Programme for data collection. The authors also thank K. Enqvist and T. Johansson (Västerbotten County Council, Umeå, Sweden) for DNA preparation and P. Soule, H. Ranu, and D.J. Hunter (Harvard School of Public Health, Boston, MA) for support with genotyping. The GLACIER Study was funded by project grants from Novo Nordisk, the Swedish Heart-Lung Foundation, the Swedish Diabetes Association, the Pålssons Foundation, the Swedish Research Council, the Umeå Medical Research Foundation, and The Heart Foundation of Northern Sweden (all to P.W.F.). F.R. was supported by a postdoctoral stipend from the Swedish Heart-Lung Foundation.

Hertfordshire: The Hertfordshire Cohort Study is supported by the Medical Research Council and Arthritis Research UK.

Inter99: The Marie Krogh Center for Metabolic Research is funded by the Novo Nordisk Foundation. The study was supported by grants from the Lundbeck Foundation Centre of Applied Medical Genomics for Personalized Disease Prediction, Prevention and Care (LuCAMP), the Danish Council for Independent Research (Medical Sciences). The Inter99 was initiated by T. Jørgensen (principal investigator (PI)), K. Borch-Johnsen (co-PI), H. Ibsen and T. F. Thomsen. The steering committee comprises the former two and C. Pisinger. The study was financially supported by research grants from

SUPPLEMENTARY DATA

the Danish Research Council, the Danish Centre for Health Technology Assessment, Novo Nordisk, Research Foundation of Copenhagen County, Ministry of Internal Affairs and Health, the Danish Heart Foundation, the Danish Pharmaceutical Association, the Augustinus Foundation, the Ib Henriksen Foundation, the Becket Foundation, and the Danish Diabetes Association.

METSIM: The METSIM Study is funded by the Academy of Finland, Diabetes Research Foundation, and Finnish Heart Disease Research Foundation.

RISC: The RISC Study is supported by European Union grant QLG1-CT-2001-01252 and AstraZeneca.

Sorbs: Financial support was received from the German Research Council (KFO-152), IZKF (B27) and the German Diabetes Association. We would like to thank Knut Krohn (Microarray Core Facility of the Interdisciplinary Centre for Clinical Research, University of Leipzig) for the genotyping/analytical support and Joachim Thiery (Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig) for clinical chemistry services.

ULSAM: Genotyping was performed by the SNP&SEQ Technology Platform in Uppsala (www.genotyping.se). The SNP Technology Platform is supported by Uppsala University, Uppsala University Hospital and the Swedish Research Council for Infrastructures.

Whitehall: The Whitehall II study has been supported by grants from the Medical Research Council; Economic and Social Research Council; British Heart Foundation; Health and Safety Executive; Department of Health; National Heart Lung and Blood Institute (HL36310), US, NIH: National Institute on Aging (AG13196), US, NIH; The Stroke Association; Agency for Health Care Policy Research (HS06516); and the John D and Catherine T MacArthur Foundation Research Networks on Successful Midlife Development and Socio-economic Status and Health. M Kivimaki is supported by NIH NHLBI (R01 HL036310-20A2) and NIA (R01 AG34454), US.

SUPPLEMENTARY DATA

Supplementary Table 1. Study descriptives and analysis metrics

Study	Genotyping method	N (SNP× BMI)	N* (SNP ×PA)	PA measurement method*	Inactive*	% Male	Age (years)		2-h glucose (mmol/L)		BMI (kg/m ²)	
							mean	SD	mean	SD	mean	SD
ARIC	Affymetrix 6.0	5085	5085	Questionnaire	1133 (22.3)	44.8	62.8	5.6	7.2	2.3	27.9	4.9
BLSA	Illumina	464	708	Questionnaire	142 (20.1)	46	49.0	16.3	6.3	1.8	24.6	3.5
BotniaPPP	iPLEX Sequenom MassARRAY	2061	2057	Kuopio Ischemic heart Disease Questionnaire	271 (19.9)	47	46.1	15.4	5.1	1.5	25.9	4.0
CHS	Illumina Human Hap- 370K chip	2724	2707	Questionnaire	542 (20.0)	38.8	72.2	5.3	7.6	2.3	26.2	4.2
CoLaus	Affymetrix 500K	425	465	Questionnaire	85 (18.3)	37.9	58.4	8.7	5.7	1.7	26.0	4.4
Ely	iPLEX Sequenom MassARRAY	1534	672	Flex HR Method	138 (20.2)	45.6	61.0	9.1	6.3	2.2	27.2	4.7
Fenland	Affymetrix 500K	1361	1320	Recent PA Questionnaire (leisure time component)	271 (19.9)	44.0	45.0	7.3	5.2	1.6	27.1	4.9
FUSION	Illumina HumanHap300	1113	871	Questionnaire	94 (10.8)	49.2	63.3	7.5	5.7	1.2	27.1	3.8
FUSION Stage 2	Sequenom iPLEX Gold SBE	670	NA	NA	NA	55.1	61.4	7.6	5.7	1.2	26.8	4.0
Framingham	Affymetrix	2694	2527	Framingham PA index	684 (27.1)	45.6	54.1	9.8	5.9	1.6	26.9	4.5
French Family Members	TaqMan	308	NA	NA	NA	47.1	37.9	8.5	5.1	0.5	29.7	7.1
French Hagueneau	TaqMan	1069	NA	NA	NA	50.0	23.0	3.7	5.3	1.2	23.4	4.0
GLACIER	iPLEX Sequenom MassARRAY	15557	15037	Umea EPIC PA Questionnaire	7243 (48.2)	40.0	52.3	8.7	6.8	1.5	26.0	4.0
Hertfordshire	iPLEX Sequenom MassARRAY	1863	459	Questionnaire	93 (20.2)	54.3	65.6	2.9	7.1	2.1	26.9	4.0

SUPPLEMENTARY DATA

Inter99	KASPar SNP Genotyping system (Kbiosciences)	5655	5547	Questionnaire	1110 (20.0)	49.5	45.9	7.9	6.0	1.5	26.1	4.3
METSIM	Sequenom iPLEX Gold SBE	5315	5315	Questionnaire	1289 (24.3)	100	58.4	6.5	6.1	1.7	26.8	3.7
NHANES	iPLEX Sequenom MassARRAY	513	522	Questionnaire	111 (21.3)	60.2	57.5	10.7	6.7	2.2	27.6	5.3
RISC	iPLEX Sequenom MassARRAY	1442	1339	Questionnaire	277 (20.7)	45.1	44.1	8.3	5.8	1.6	25.7	4
Roche	iPLEX Sequenom MassARRAY	590	NA	NA	NA	45.0	51.6	12.7	6.0	2.2	27.6	6.4
Sorbs	Affymetrix 500K	582	582	Questionnaire	330 (56.7)	40.3	47.5	15.9	5.3	2.1	26.8	4.7
ULSAM	Illumina MetaboChip + BeadExpress	930	957	Questionnaire	36 (3.8)	100	71	0.6	7.3	2.3	26.1	3.2
Whitehall II	TaqMan	4306	4306	Questionnaire	973 (20.2)	73.0	60.5	5.8	6.4	1.8	26.5	4.0

SUPPLEMENTARY DATA

Supplementary Figure 1. The association of rs1260326 with 2-h glucose is shown in different BMI strata.

SNP association with 2-h glucose in BMI strata

